Patents by Inventor Xiaomao Li
Xiaomao Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11887485Abstract: A control method and system for collaborative interception by multiple unmanned surface vessels are provided. The method includes obtaining task environment information of each unmanned surface vessel in an unmanned surface vessel group at a current moment, estimating interception point information of the intruding target at the current moment by using a Kalman filter according to the task environment information of the unmanned surface vessels at the current moment, determining process state information of each unmanned surface vessel at the current moment, inputting the process state information of each unmanned surface vessel at the current moment into a corresponding intruding target interception policy output model respectively to obtain an execution action of each unmanned surface vessel at a next moment to intercept the intruding target. The application can intercept the intruding target accurately.Type: GrantFiled: September 7, 2021Date of Patent: January 30, 2024Assignees: Shanghai University, Chongqing UniversityInventors: Huayan Pu, Yuan Liu, Jun Luo, Zhijiang Xie, Jiajia Xie, Xiaomao Li, Zhou Su, Yan Peng, Hengyu Li, Shaorong Xie
-
Publication number: 20220214688Abstract: A method and system for controlling multi-unmanned surface vessel (USV) collaborative search are disclosed which relate to the technical field of the marine intelligent USV collaborative operation. The method includes determining a task region of a USV team; determining environmental perception information corresponding to each of the USVs at the current moment according to the task region and the probability graph mode; inputting the environmental perception information corresponding to each of the USVs at the current moment into the corresponding target search strategy output model respectively to obtain an execution action of each of the USVs at the next moment; sending the execution action of each of the USVs at the next moment to a corresponding USV execution structure to search for underwater targets within the task region. The target search strategy output model is obtained by training based on a training sample and a DDQN network structure.Type: ApplicationFiled: September 8, 2021Publication date: July 7, 2022Inventors: Huayan PU, Yuan LIU, Jun LUO, Zhijiang XIE, Xiaomao LI, Jiajia XIE, Zhou SU, Yan PENG, Shaorong XIE
-
Publication number: 20220215758Abstract: A control method and system for collaborative interception by multiple unmanned surface vessels are provided. The method includes obtaining task environment information of each unmanned surface vessel in an unmanned surface vessel group at a current moment, estimating interception point information of the intruding target at the current moment by using a Kalman filter according to the task environment information of the unmanned surface vessels at the current moment, determining process state information of each unmanned surface vessel at the current moment, inputting the process state information of each unmanned surface vessel at the current moment into a corresponding intruding target interception policy output model respectively to obtain an execution action of each unmanned surface vessel at a next moment to intercept the intruding target. The application can intercept the intruding target accurately.Type: ApplicationFiled: September 7, 2021Publication date: July 7, 2022Inventors: Huayan PU, Yuan LIU, Jun LUO, Zhijiang XIE, Jiajia XIE, Xiaomao LI, Zhou SU, Yan PENG, Hengyu LI, Shaorong XIE
-
Publication number: 20090123529Abstract: There is provided an immunological composition that comprises a nucleic acid vector which includes a promoter region operably linked to a coding sequence encoding the human metapneumovirus F antigen or the human metapneumovirus G antigen. The immunological composition is useful for administering to an individual to elicit an immune response to human metapneumovirus in the individual and for the generation of diagnostic reagents for hMPV.Type: ApplicationFiled: October 3, 2006Publication date: May 14, 2009Inventor: Xiaomao Li
-
Patent number: 7012096Abstract: The present invention is directed to a composition for treating burns. The composition comprises a therapeutically effective amount of one or more weak organic acid compatible with human skin, in a pharmacologically effective carrier delivered at a pH of about 2.5–4.5. The weak organic acid is preferably selected from the group consisting of acetic acid, vinegar, citric acid and combinations thereof and the pharmacologically effective carrier is preferably an aqueous based carrier, more preferably a gel form, utilizing a CARBOPOL as a gelling agent. The composition may also include one or more other agents selected from sun blocking agents, skin moisturizing agents, herb extracts and antimicrobial agents.Type: GrantFiled: August 30, 2002Date of Patent: March 14, 2006Assignee: Palladin Healthcare International, Inc.Inventors: Michael H. Dosch, Xiaomao Li, Kurt Osterman
-
Publication number: 20050214874Abstract: This invention relates to the treatment and diagnosis of Type-1 Diabetes (T1D); particularly to the use of glial fibrillary acidic protein (GFAP) as a mediator of the disease; and most particularly to GFAP binding proteins useful for prediabetes screening and/or staging.Type: ApplicationFiled: May 18, 2005Publication date: September 29, 2005Applicant: Syn X Pharma, Inc.Inventors: George Jackowski, Xiaomao Li
-
Patent number: 6677127Abstract: Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such vectors may be used to immunize a host, including a human host, by administration thereto. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.Type: GrantFiled: September 13, 1999Date of Patent: January 13, 2004Assignee: Aventis Pasteur LimitedInventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
-
Publication number: 20030054414Abstract: This invention relates to the treatment and diagnosis of Type-1 Diabetes (T1D); particularly to the use of glial fibrillary acidic protein (GFAP) as a mediator of the disease; and most particularly to GFAP binding proteins useful for prediabetes screening and/or staging.Type: ApplicationFiled: September 17, 2001Publication date: March 20, 2003Inventors: George Jackowski, Xiaomao Li
-
Patent number: 6486135Abstract: Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. The nucleotide sequence encloding the RSV F protein may lack a sequence encoding the homologous signal peptide but possessing a heterologous signal peptide enhancing RSV F protein expression. Such non-replicating vectors, including plasmids, also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such non-replicating vectors may be used to immunize a host against disease caused by infection with RSV, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purpose. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.Type: GrantFiled: May 12, 2000Date of Patent: November 26, 2002Assignee: Aventis Pasteur LimitedInventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
-
Patent number: 6475780Abstract: A DNA vector comprises a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus DNA genome replication regions, and a second DNA sequence encoding a paramyxovirus protein, particularly a respiratory syncytial virus fusion (RSV F) protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein, the first and second DNA sequences being under the transcriptional control of a promoter, preferably a cytomegalovirus promoter, which may include Intron A. Such vectors also contain a further nucleotide sequence located between the promoter sequence and the alphavirus sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo.Type: GrantFiled: October 20, 2000Date of Patent: November 5, 2002Assignee: Aventis Pasteur LimitedInventors: Mark Parrington, Xiaomao Li, Michel H. Klein
-
Patent number: 6469066Abstract: The present invention is directed to a composition for treating burns. The composition comprises a therapeutically effective amount of one or more weak organic acids compatible with human skin, in a pharmacologically effective carrier delivered at a pH of about 2.5-4.5. The weak organic acid is preferably selected from the group consisting of acetic acid, vinegar, citric acid and combinations thereof and the pharmacologically effective carrier is preferably an aqueous based carrier, more preferably a gel form, utilizing a CARBOPOL as a gelling agent. The composition may also include one or more other agents selected from sun blocking agents, skin moisturizing agents, herb extracts and antimicrobial agents.Type: GrantFiled: June 9, 2000Date of Patent: October 22, 2002Assignee: Palladin Healthcare International, Ltd.Inventors: Michael H. Dosch, Xiaomao Li, Kurt Osterman
-
Patent number: 6083925Abstract: Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. The nucleotide sequence encloding the RSV F protein may lack a sequence encoding the homologous signal peptide but possessing a heterologous signal peptide enhancing RSV F protein expression. Such non-replicating vectors, including plasmids, also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such non-replicating vectors may be used to immunize a host against disease caused by infection with RSV, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purpose. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.Type: GrantFiled: March 5, 1999Date of Patent: July 4, 2000Assignee: Connaught Laboratories LimitedInventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
-
Patent number: 6022864Abstract: Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F protein enclosing sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such vectors may be used to immunize a host, including a human host, by administration thereto. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.Type: GrantFiled: March 27, 1998Date of Patent: February 8, 2000Assignee: Connaught Laboratories LimitedInventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
-
Patent number: 6019980Abstract: Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such vectors may be used to immunize a host, including a human host, by administration thereto. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.Type: GrantFiled: June 7, 1995Date of Patent: February 1, 2000Assignee: Connaught Laboratories LimitedInventors: Xiaomao Li, Mary E. Ewashysyn, Michel H. Klein
-
Patent number: 6017897Abstract: Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. Such non-replicating vectors, including plasmids, also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such non-replicating vectors may be used to immunize a host against disease caused by infection with RSV, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purpose. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.Type: GrantFiled: July 18, 1997Date of Patent: January 25, 2000Assignee: Pasteur Merieux Connaught CanadaInventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
-
Patent number: 5880104Abstract: Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such vectors may be used to immunize a host, including a human host, by administration thereto. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.Type: GrantFiled: May 1, 1997Date of Patent: March 9, 1999Assignee: Connaught Laboratories LimitedInventors: Xiaomao Li, Mary E. Ewashysyn, Michel H. Klein
-
Patent number: 5843913Abstract: Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such vectors may be used to immunize a host, including a human host, by administration thereto. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.Type: GrantFiled: June 7, 1996Date of Patent: December 1, 1998Assignee: Connaught Laboratories LimitedInventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein